Unknown

Dataset Information

0

Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor.

ABSTRACT: For a subpopulation of acute myeloid leukemia (AML) patients, the mutationally activated tyrosine kinase FLT3, has emerged as a promising target for therapy. The development of drug resistance due to mutation is a growing concern for mutant FLT3 inhibitors, such as PKC412, Quizartinib, PLX3397, and Crenolanib. Thus, there is a need to develop novel FLT3 inhibitors that overcome these mutations. Here we report the development of a novel type I ATP competitive inhibitor, JH-IX-179, that is extremely potent and selective for FLT3. JH-IX-179 also has the highest affinity for three constitutively active isoforms of FLT3 (FLT3-ITD, FLT3-N841I, and FLT3-D835V) compared to a panel 456 other kinases. The unique and specific kinase inhibition profile suggests that this chemotype may represent an attractive starting point for the development of further improved FLT3 inhibitors with therapeutic potential in tumors harboring deregulated FLT3 activity.

SUBMITTER: Hatcher JM 

PROVIDER: S-EPMC4867484 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor.

Hatcher John M JM   Weisberg Ellen E   Sim Taebo T   Stone Richard M RM   Liu Suiyang S   Griffin James D JD   Gray Nathanael S NS  

ACS medicinal chemistry letters 20160308 5

For a subpopulation of acute myeloid leukemia (AML) patients, the mutationally activated tyrosine kinase FLT3, has emerged as a promising target for therapy. The development of drug resistance due to mutation is a growing concern for mutant FLT3 inhibitors, such as PKC412, Quizartinib, PLX3397, and Crenolanib. Thus, there is a need to develop novel FLT3 inhibitors that overcome these mutations. Here we report the development of a novel type I ATP competitive inhibitor, JH-IX-179, that is extreme  ...[more]

Similar Datasets

Unknown Crenolanib is a selective type I pan-FLT3 inhibitor.
| S-EPMC3986131 | biostudies-literature
Unknown Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML.
| S-EPMC5053879 | biostudies-literature
Unknown Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor.
| S-EPMC6512007 | biostudies-literature
Unknown Discovery of CX-6258. A Potent, Selective, and Orally Efficacious pan-Pim Kinases Inhibitor.
| S-EPMC4025662 | biostudies-literature
Unknown Discovery of the Highly Selective and Potent STAT3 Inhibitor for Pancreatic Cancer Treatment.
| S-EPMC10979493 | biostudies-literature
Unknown Momelotinib is a highly potent inhibitor of FLT3-mutant AML.
| S-EPMC8864657 | biostudies-literature
Unknown Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate).
| S-EPMC4018163 | biostudies-literature
Unknown Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.
| S-EPMC3109749 | biostudies-literature
Unknown Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor.
| S-EPMC6900553 | biostudies-literature
Unknown Discovery of Highly Potent Small Molecule Pan-Coronavirus Fusion Inhibitors.
| S-EPMC10141620 | biostudies-literature